Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 2c, Revenues Miss; Offers FY20 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street set for weekly gains with earnings, inflation data on tap
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 4.57 +0.04 (0.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.53 | 52 Week High | $18.00 | |||
| Open | $4.51 | 52 Week Low | $6.91 | |||
| Day High | $4.58 | P/E | N/A | |||
| Day Low | $4.47 | EPS | $-0.67 | |||
| Volume | 331,465 | |||||
